Status:

COMPLETED

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

Lead Sponsor:

Ascelia Pharma AB

Conditions:

Known or Suspected Focal Liver Lesions

Severe Renal Impairment

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. ...

Detailed Description

The overall objective of this multicenter, open-label, study is to evaluate the safety and diagnostic efficacy of Mangoral in participants with known or suspected focal liver lesions and severe renal ...

Eligibility Criteria

Inclusion

  • Male and female participants 18 years and older.
  • Known or suspected focal liver lesions based on medical history and previous laboratory and/or imaging examinations.
  • Severe renal impairment (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2) based on medical history and previous laboratory examinations, at least once, within the last 3 months prior to the Baseline Visit, or participants with an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours or ≥ 50% within 7 days prior to the Baseline Visit.

Exclusion

  • Participants with simple liver cysts only.
  • Any investigational drug or device within 6 weeks prior to the Baseline Visit.
  • Any magnetic resonance imaging (MRI) contrast media within 6 weeks prior to Baseline Visit or scheduled to receive any contrast medium before the last study visit.
  • Participants with severe hepatic impairment (according to Child-Pugh score C).
  • Participants scheduled for surgery before last study visit.
  • Participants with encephalopathy / neurodegenerative or acute neurological disorders.
  • Participants with hemochromatosis.

Key Trial Info

Start Date :

February 19 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 17 2023

Estimated Enrollment :

87 Patients enrolled

Trial Details

Trial ID

NCT04119843

Start Date

February 19 2020

End Date

February 17 2023

Last Update

February 6 2025

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

Mayo Clinic - Arizona

Scottsdale, Arizona, United States, 85259

2

University of California at Los Angeles Ronald Reagan Medical Center

Los Angeles, California, United States, 90095

3

Stanford University School of Medicine

Stanford, California, United States, 94305

4

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States, 32224